This drug is very effective in the treatment of corona, reduces the risk of hospitalization and death by 50 percent
A new drug from America has proved to be very effective in the treatment of corona. Merck & Co.'s oral drug molnupiravir could reduce the death or need for hospitalization in critical patients by 50 percent. On Friday, the company claimed that the results of this oral drug have turned out to be very good in the interim clinical trial. The company said in a statement that the company plans to obtain emergency permission for the drug in the US as soon as possible.
An interim analysis of a Phase-3 study based on 775 trial participants found that 7.3 percent of patients treated with molanupiravir were hospitalized within 29 days. Of the patients who received the placebo, 14.1 percent were hospitalized or died by day 29. No deaths occurred in patients who were given molanupiravir within 29 days, compared to eight deaths in placebo-treated patients.
The efficacy of the drug was not affected by the time of onset of symptoms or the underlying risk factor. Furthermore, based on participants with available viral sequencing data (approximately 40 percent of participants), mollupiravir demonstrated consistent efficacy in the viral variants gamma, delta, and mu.
"With these promising results, we are optimistic that molanupiravir could become an important drug as part of the global effort to fight the coronavirus pandemic," Merck CEO and President Robert M Davis said in the statement.
Explain that Phase 3 has been tested at more than 170 sites in countries including the US, Brazil, Italy, Japan, South Africa, Taiwan, and Guatemala. Molanupiravir has also been shown to be active in several preclinical models of SARS-CoV-2. Including prophylaxis, treatment, and prevention of transmission. Therefore, it is believed that Molnupiravir may be the first oral antiviral drug for corona.